Event date
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use.
  • CMHC
  • 12.00 ACPE Pharmacy
  • 12.00 AMA PRA Category 1 Credit
  • 12.00 ANCC
  • 12.00 Participation
The recordings from the 2023 Women’s Cardiometabolic Health and Wellness Masterclass are now available. Led by co-chairs Pam R. Taub, MD and Erin D. Michos, MD, MHS, experts in a multitude of women's health topics explored the significant differences in risk factors, symptom presentation, preventive strategies, and treatment for cardiometabolic diseases in women, as well as important implications for patient care.
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
Despite advances, there are significant gaps in the diagnosis and treatment of aortic stenosis (AS) in women. Transcatheter aortic valve replacement (TAVR) has emerged as a viable treatment option in this setting, having demonstrated increased efficacy and safety for the treatment of AS in women. This activity covers important updates in the screening, diagnosis, and risk stratification of women with AS, as well as practical considerations for TAVR.
  • PAINWeek
  • 8.25 AANP
  • 8.25 AAPA Category I CME
  • 8.25 ACCME (All Other)
  • 8.25 ACCME (MD/DO Only)
This activity will provide comprehensive and up-to-date information regarding the most recent and relevant laws and clinical practice guidelines regarding the safe and effective management and treatment of pain, including opioid and other substance use disorders. The 8-course series will yield practical guidance for prescribing clinicians who manage patients with pain and/or substance use disorders, including detailed information on appropriate treatment selection and management, risk mitigation strategies, and implementation of diversion and surveillance tools for controlled substances.
  • CMHC
  • 2.25 ACPE Pharmacy
  • 2.25 AMA PRA Category 1 Credit
  • 2.25 ANCC
  • 2.25 Participation
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), including in the development of hypertension and risk of adverse cardiovascular outcomes. Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including patients with insufficient or impaired sleep, as well as practical strategies to minimize the impact of elevated sodium.
  • PAINWeek
Cannabinoid prescription medications are available across the globe and right here in America. More are in the pipeline. Where do and will these products be placed and how will they work?
  • CMHC
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 Participation
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment.
  • CMHC
  • 19.25 ACPE Pharmacy
  • 19.25 AMA PRA Category 1 Credit
  • 19.25 ANCC
  • 19.25 CDE
  • 19.25 Participation
The recordings from the 18th Annual meeting are now available.